Emerging targeted therapies in haematological malignancies

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M. Vose, MD, MBA, of the University of Nebraska Medical Center, Omaha, NE, discusses the recent development of molecularly targeted therapies in the management of haematological malignancies.

Emerging targeted agents include monoclonal antibody (mAb) targeting Signaling Lymphocytic Activation Molecule F7 (SLAMF7), elotuzumab, for multiple myeloma; anti-CD38 mAb, daratumumab, for multiple myeloma; anti-CD20 mAb, obinutuzumab, for chronic lymphocytic leukaemia (CLL); and ibrutinib plus bendamustine for CLL.